General
Preferred name
budesonide
Synonyms
17-PA ()
CPD000058337 ()
Entocort ()
Pulmicort ()
Rhinocort ()
Symbicort-budesonide ()
Jorveza ()
Budesonide component of breztri ()
MAP0010 ()
R01AD05 ()
DuoResp Spiromax ()
Rhinocort allergy ()
Pulmicort Flexhaler ()
Rhinocort Aqua 64 ()
Kinpeygo ()
Pulmicort Respules ()
Budesonide component of uceris ()
Entocort CR ()
Ortikos ()
Cortiment ()
Budenofalk ()
Budelin Novolizer ()
Entocort Ec ()
MAP-0010 ()
Aircort ()
Uceris ()
Preferid ()
Symbicort ()
S-1320 ()
NSC-757788 ()
Budesonide component of airsupra ()
Budesonide component of symbicort ()
Rhinocort Aqua ()
Budesonida ()
Tarpeyo ()
Eohilia ()
Pulmaxan ()
Budeflam Aquanase ()
Pulmicort L.S. ()
Budesonide-d8 ()
AIRCORT ()
BUDEFLAM AQUANASE ()
BUDELIN NOVOLIZER ()
BUDENOFALK ()
BUDESONIDA ()
BUDESONIDE COMPONENT OF AIRSUPRA ()
BUDESONIDE COMPONENT OF BREZTRI ()
BUDESONIDE COMPONENT OF SYMBICORT ()
BUDESONIDE COMPONENT OF UCERIS ()
CORTIMENT ()
DUORESP SPIROMAX ()
ENTOCORT CR ()
ENTOCORT EC ()
EOHILIA ()
JORVEZA ()
KINPEYGO ()
ORTIKOS ()
PREFERID ()
PULMAXAN ()
PULMICORT FLEXHALER ()
PULMICORT L.S. ()
PULMICORT RESPULES ()
RHINOCORT ALLERGY ()
RHINOCORT AQUA ()
RHINOCORT AQUA 64 ()
SYMBICORT ()
TARPEYO ()
UCERIS ()
P&D ID
PD002795
CAS
51333-22-3
1105542-94-6
Tags
available
drug
Approved by
EMA
PMDA
FDA
First approval
1994
Drug indication
Allergic rhinitis
Asthma
Drug Status
approved
Max Phase
4.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
ABSORPTION Absorption is complete following oral administration. The pharmacokinetic parameters of the inhaled powder formulation are as follows: ; Tmax = 30 minutes; ; Absolute systemic availability = 39%.; When a single oral administration of 9 mg of Uceris are given, the pharmacokinetic parameters are as follows:; Tmax = 13.3 ± 5.9 hours;; Cmax = 1.35 ± 0.96 ng/mL;; AUC = 16.43 ± 10.52 ng·hr/mL.; It is important to note that the parameters have a high degree of variability. ; When a single oral administration of Entocort EC are given, the pharmacokinetic parameters are as follows:; Tmax = 3- 600 minutes; ; Cmax = 5 nmol/L;; AUC = 30 nmol•hr/L. ;
DESCRIPTION Budesonide is a glucocorticoid steroid. The INN document specifies that the approved drug consists of a racemic mixture of two epimers, based on the stereocentre of the carbon where the butyl chain meets the rest of the molecule. Our structure does not specify strereochemistry at this point and represents the mixture. The two epimers are represented by CID 40000 and CID 63006.

COVID-19: Results from a Phase 2 clinical trial have shown that a short duration administration of budesonide in the early phase of SARS-CoV-2 infection reduces both the likelihood of needing urgent medical care and time to recovery . (GtoPdb)
DESCRIPTION Budesonide, an inhaled glucocortical steroid, is an orally active glucocorticoid receptor agonist. Budesonide decreases the size of lung tumors, reverses DNA hypomethylation and modulates mRNA expression of genes. Budesonide is an anti-inflammatory agent used for asthma[1][2][3].
DESCRIPTION Selective estrogen receptor modulator (SERM), selective for ERalpha (Tocris Bioactive Compound Library)
DESCRIPTION Synthetic glucocorticoid; anti-inflammatory and chemopreventive (Tocriscreen Plus)
DESCRIPTION Anti-inflammatory glucocorticoid (LOPAC library)
DESCRIPTION Antagonist of neurosteroid potentiation and direct gating of GABAA (Tocriscreen Total)
DESCRIPTION Synthetic glucocorticoid; anti-inflammatory and chemopreventive (Tocriscreen Total)
DESCRIPTION Budesonide (Pulmicort), an anti-inflammatory corticosteroid, has shown the effective glucocorticoid activitie and few mineralocorticoid activities. According to reports, Budesonide has extensively inhibitory effects against multiple cells types and mediators referred to allergic and nonallergic-mediated inflammatory. What's more, the anti-inflammatory action of budesonide has been revealed to contribute to the effectiveness of asthma. (TargetMol Bioactive Compound Library)
Cell lines
2
Organisms
1
Compound Sets
31
AdooQ Bioactive Compound Library
A10166
Bioprocess diversity set
Cayman Chemical Bioactives
15407
30046
ChEMBL Approved Drugs
CHEMBL1370
ChEMBL Drugs
CHEMBL1370
Concise Guide to Pharmacology 2017/18
7434
Concise Guide to Pharmacology 2019/20
7434
Concise Guide to Pharmacology 2021/22
7434
Concise Guide to Pharmacology 2023/24
7434
CZ-OPENSCREEN Bioactive Library
DrugBank
DB01222
DrugBank Approved Drugs
DB01222
DrugCentral
419
DrugCentral Approved Drugs
419
DrugMAP
DMJIBAW
DrugMAP Approved Drugs
DMJIBAW
EU-OPENSCREEN Bioactive Compound Library
EOS101610
EUbOPEN Chemogenomics Library
EUB0002135
Guide to Pharmacology
7434
LOPAC library
LSP-MoA library (Laboratory of Systems Pharmacology)
CHEMBL1370
MedChem Express Bioactive Compound Library
HY-13580
Natural product-based probes and drugs
NCATS Inxight Approved Drugs
Q3OKS62Q6X
NIH Clinical Collections (NCC)
Prestwick Chemical Library
ReFrame library
TargetMol Bioactive Compound Library
T0094
Tocris Bioactive Compound Library
2671
Tocriscreen Plus
2671
Tocriscreen Total
External IDs
51
Properties
(calculated by RDKit )
Molecular Weight
430.24
Hydrogen Bond Acceptors
6
Hydrogen Bond Donors
2
Rotatable Bonds
4
Ring Count
5
Aromatic Ring Count
0
cLogP
2.72
TPSA
93.06
Fraction CSP3
0.76
Chiral centers
9.0
Largest ring
6.0
QED
0.71
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target Type
Nuclear Receptors
Selectivity
Cortisol
Biological process
Mitosis & chromosome segregation
Target
Glucocorticoid Receptor
ADC Payload
ADC Cytotoxin
Primary Target
Glucocorticoid Receptors
Biosynthetic Origin
Terpenoid (Steroid)
Therapeutic Indication
Antiasthmatic
Therapeutic Class
Respiratory
Antiinflammatory Agents
Pathway
Antibody-drug Conjugate/ADC Related
Endocrinology/Hormones
Immunology/Inflammation
Vitamin D Related/Nuclear Receptor
Recommended Cell Concentration
None
Source data